0       0

2015 ISHLT Annual Meeting and Scientific Sessions


CCS24a - CONCURRENT SESSION 24: Immunosuppression: The Tor Inhibitors Strike Back -- The Effect of Everolimus Initiation and Early Calcineurin Inhibitor Withdrawal on Allograft Vasculopathy in De-Novo Heart Transplant Recipients: Results of the SCHEDULE Trial Afte


Apr 17, 2015 11:00am ‐ Apr 17, 2015 11:15am

Description

Presentation Includes
 

  • The Effect of Everolimus Initiation and Early Calcineurin Inhibitor Withdrawal on Allograft Vasculopathy in De-Novo Heart Transplant Recipients: Results of the SCHEDULE Trial After 36 Months
  • Long Term Outcomes in Thoracic Transplant Recipients After Conversion to Everolimus With Reduced Calcineurin Inhibitor Within a Multicenter, Open-Label, Randomized Trial
  • Use of Rapamycin One-Year Post Heart Transplantation Stabilizes Transplant Allograft Vasculopathy - The Mid America Experience
  • A Multi-Center, Randomized, Open-Label, Parallel Group Phase IV Trial Investigating the Outcome on Renal Function, Efficacy and Safety of CNI-Reduction or Elimination With Everolimus in De Novo Heart Transplant Recipients: The MANDELA Study Design
  • Sirolimus Based Immunosuppression Results in Lower Incidence of Post-Transplantation Lymphoproliferative Disorders in Heart Transplant Recipients
  • Effect of Everolimus Immunotherapy on HLA Antibody Production in Heart Transplantation

Speaker(s):

  • Satish Arora, MD, PhD, Oslo University Hospital, Oslo, Norway

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content